Cash from Financing (Quarterly) Chart

View Cash from Financing (Quarterly) for NTRA.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View Cash from Financing (Quarterly) Chart
Start Trial

Historical Cash from Financing (Quarterly) Data

View and export this data back to 2014. Start Trial.
Date Value
June 30, 2026 12.21M
March 31, 2026 3.758M
December 31, 2025 32.41M
September 30, 2025 1.935M
June 30, 2025 12.58M
March 31, 2025 0.544M
December 31, 2024 10.97M
September 30, 2024 1.72M
June 30, 2024 11.04M
March 31, 2024 6.466M
December 31, 2023 6.845M
September 30, 2023 236.00M
June 30, 2023 9.312M
March 31, 2023 2.301M
December 31, 2022 468.17M
September 30, 2022 1.393M
June 30, 2022 8.918M
March 31, 2022 4.156M
December 31, 2021 8.515M
September 30, 2021 554.76M
June 30, 2021 8.344M
March 31, 2021 4.57M
December 31, 2020 11.79M
September 30, 2020 275.62M
June 30, 2020 209.60M
Date Value
March 31, 2020 3.826M
December 31, 2019 220.62M
September 30, 2019 4.433M
June 30, 2019 113.15M
March 31, 2019 2.578M
December 31, 2018 3.03M
September 30, 2018 104.64M
June 30, 2018 5.487M
March 31, 2018 0.565M
December 31, 2017 2.035M
September 30, 2017 75.90M
June 30, 2017 2.029M
March 31, 2017 0.413M
December 31, 2016 2.492M
September 30, 2016 0.454M
June 30, 2016 8.932M
March 31, 2016 1.306M
December 31, 2015 15.32M
September 30, 2015 178.00M
June 30, 2015 -2.448M
March 31, 2015 -0.588M
December 31, 2014
September 30, 2014 -0.949M
June 30, 2014 -1.349M
March 31, 2014 -0.125M

Cash From Financing Definition

Represents the net cash flow resulting from the company's financing activities. Financing activities represent movement in the company's debt and share capital and other activities.

Read full definition.

Cash from Financing (Quarterly) Range, Past 5 Years

View Cash from Financing (Quarterly) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Cash from Financing (Quarterly) Benchmarks

View Cash from Financing (Quarterly) Benchmarks
Start Trial
Guardant Health, Inc. 23.01M
CareDx, Inc. -15.50M
Myriad Genetics, Inc. 2.20M
BioRestorative Therapies, Inc. 4.441M
Exagen, Inc. -0.37M